National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/14657

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04
Route: GAVAGE                                                                                                     Time: 09:52:31

                                                            FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFBINARYMIX

       Lock Date:  03/27/02

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 004    300 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 006    300 NG /3000 UG






























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 09:52:31  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          98           80           98           80                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                22           10           19           13                                     
    Natural Death                                      8           12           10           10                                     
    Dosing Accident                                    1                                      1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                22           28           24           27                                     
                                                                                                                                    
  Animals Examined Microscopically                    53           50           53           51                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (53)         (50)         (52)         (50)                                   
   Intestine Large, Rectum                            (53)         (50)         (53)         (51)                                   
      Schwannoma Malignant, Metastatic, Vagina                                   1 (2%)                                             
   Intestine Small, Duodenum                          (53)         (50)         (52)         (50)                                   
      Leiomyoma                                                                  2 (4%)                                             
   Intestine Small, Jejunum                           (53)         (50)         (52)         (51)                                   
      Fibrosarcoma                                                                            1 (2%)                                
      Leiomyosarcoma                                   1 (2%)                                                                       
   Intestine Small, Ileum                             (53)         (50)         (52)         (50)                                   
   Liver                                              (53)         (50)         (52)         (51)                                   
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
      Cholangiocarcinoma                                            6 (12%)      4 (8%)      12 (24%)                               
      Cholangiocarcinoma, Multiple                                  1 (2%)       5 (10%)     13 (25%)                               
      Hemangioma                                       1 (2%)                                                                       
      Hepatocellular Adenoma                                                     5 (10%)     14 (27%)                               
      Hepatocellular Adenoma, Multiple                              2 (4%)                    7 (14%)                               
      Hepatocholangioma                                                          2 (4%)       1 (2%)                                
      Hepatocholangioma, Multiple                                                             1 (2%)                                
   Mesentery                                          (47)         (31)         (47)         (47)                                   
   Oral Mucosa                                        (12)         (28)         (30)         (41)                                   
      Gingival, Squamous Cell Carcinoma                             3 (11%)      5 (17%)      6 (15%)                               
   Pancreas                                           (53)         (49)         (52)         (49)                                   
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
      Acinus, Adenoma                                                            3 (6%)       1 (2%)                                
      Acinus, Carcinoma                                                          1 (2%)       1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 09:52:31  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (53)         (50)         (53)         (50)                                   
      Fibrosarcoma, Metastatic, Lung                                             1 (2%)                                             
      Fibrous Histiocytoma, Metastatic, Skeletal                                                                                    
          Muscle                                       1 (2%)                                                                       
      Schwannoma Malignant                                          1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (53)         (49)         (52)         (51)                                   
      Adenoma                                                                    1 (2%)                                             
      Carcinoma                                                                               1 (2%)                                
   Adrenal Medulla                                    (52)         (49)         (52)         (49)                                   
      Pheochromocytoma Benign                          2 (4%)       1 (2%)       1 (2%)       2 (4%)                                
      Bilateral, Pheochromocytoma Benign               1 (2%)                                                                       
   Islets, Pancreatic                                 (53)         (49)         (52)         (49)                                   
      Adenoma                                          1 (2%)                                 1 (2%)                                
   Pituitary Gland                                    (53)         (50)         (52)         (51)                                   
      Carcinoma                                        1 (2%)                                                                       
      Pars Distalis, Adenoma                          22 (42%)     19 (38%)     17 (33%)      9 (18%)                               
      Pars Distalis, Carcinoma                                      1 (2%)                                                          
   Thyroid Gland                                      (53)         (49)         (52)         (50)                                   
      Bilateral, C-Cell, Adenoma                       2 (4%)                    3 (6%)       1 (2%)                                
      C-Cell, Adenoma                                  8 (15%)      6 (12%)     12 (23%)      7 (14%)                               
      C-Cell, Carcinoma                                4 (8%)       1 (2%)       1 (2%)                                             
      Follicular Cell, Adenoma                                      1 (2%)       1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (53)         (49)         (53)         (50)                                   
      Adenoma                                          1 (2%)                                                                       
   Ovary                                              (53)         (48)         (52)         (50)                                   
      Granulosa Cell Tumor Malignant                   1 (2%)                    1 (2%)                                             
      Granulosa Cell Tumor Benign                                                1 (2%)                                             
      Luteoma                                                                                 1 (2%)                                
   Uterus                                             (53)         (50)         (52)         (50)                                   
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 09:52:31  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - cont                                                                                                               
      Carcinoma                                                     1 (2%)                                                          
      Carcinoma, Multiple                                                                     1 (2%)                                
      Fibrosarcoma                                                               1 (2%)                                             
      Polyp Stromal                                    5 (9%)       3 (6%)       6 (12%)                                            
      Polyp Stromal, Multiple                          3 (6%)       1 (2%)                    1 (2%)                                
      Schwannoma Malignant                                          1 (2%)       2 (4%)       2 (4%)                                
      Schwannoma Malignant, Metastatic, Vagina                                   1 (2%)                                             
      Squamous Cell Carcinoma                          1 (2%)       1 (2%)       2 (4%)                                             
      Cervix, Granular Cell Tumor Benign                                         1 (2%)                                             
      Cervix, Squamous Cell Carcinoma                               1 (2%)       2 (4%)                                             
   Vagina                                             (1)          (1)          (1)                                                 
      Sarcoma                                                       1 (100%)                                                        
      Schwannoma Malignant                                                       1 (100%)                                           
      Squamous Cell Carcinoma                          1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (4)          (2)          (7)          (5)                                    
      Mediastinal, Carcinoma, Metastatic, Uterus                                              1 (20%)                               
   Lymph Node, Mesenteric                             (53)         (49)         (52)         (49)                                   
   Spleen                                             (53)         (49)         (52)         (49)                                   
   Thymus                                             (53)         (48)         (50)         (47)                                   
      Squamous Cell Carcinoma, Metastatic, Lung                                  1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (53)         (50)         (53)         (51)                                   
      Adenoma                                          2 (4%)       1 (2%)                    1 (2%)                                
      Carcinoma                                        6 (11%)      1 (2%)       1 (2%)       4 (8%)                                
      Carcinoma, Multiple                              2 (4%)                    1 (2%)                                             
      Fibroadenoma                                    27 (51%)     21 (42%)     25 (47%)     17 (33%)                               
      Fibroadenoma, Multiple                          13 (25%)      8 (16%)      9 (17%)     12 (24%)                               
   Skin                                               (53)         (50)         (53)         (51)                                   
      Fibroma                                          2 (4%)       2 (4%)       1 (2%)       1 (2%)                                
      Fibrosarcoma                                                  1 (2%)                                                          
      Lipoma                                                                     1 (2%)                                             
      Neural Crest Tumor                                            1 (2%)                                                          
      Squamous Cell Papilloma                                                                 1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 09:52:31  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                    (1)          (1)          (1)          (3)                                    
      Carcinoma, Metastatic, Uterus                                                           1 (33%)                               
      Fibrosarcoma, Metastatic, Lung                                             1 (100%)                                           
      Fibrous Histiocytoma                             1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (53)         (50)         (52)         (51)                                   
      Carcinoma, Metastatic, Pituitary Gland           1 (2%)       1 (2%)                                                          
      Granular Cell Tumor Malignant                                              1 (2%)                                             
      Granular Cell Tumor Benign                                    1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (53)         (50)         (53)         (50)                                   
      Carcinoma, Metastatic, Mammary Gland             1 (2%)                                                                       
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
      Cystic Keratinizing Epithelioma                               1 (2%)       1 (2%)       1 (2%)                                
      Cystic Keratinizing Epithelioma, Multiple                                               1 (2%)                                
      Fibrous Histiocytoma, Metastatic, Skeletal                                                                                    
          Muscle                                       1 (2%)                                                                       
      Squamous Cell Carcinoma                                                    1 (2%)                                             
      Mediastinum, Fibrosarcoma                                                  1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (53)         (49)         (52)         (51)                                   
      Squamous Cell Carcinoma, Metastatic, Oral                                                                                     
          Mucosa                                                                 1 (2%)                                             
   Zymbal's Gland                                                               (1)                                                 
      Adenoma                                                                    1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (53)         (48)         (52)         (51)                                   
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
      Nephroblastoma                                                             1 (2%)                                             
      Renal Tubule, Adenoma                            1 (2%)                                                                       
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 09:52:31  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
URINARY SYSTEM - cont                                                                                                               
   Urinary Bladder                                    (53)         (49)         (52)         (50)                                   
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
      Papilloma                                        1 (2%)                                                                       
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(53)        *(50)        *(53)        *(51)                                   
      Lymphoma Malignant                                            1 (2%)       2 (4%)       1 (2%)                                
      Mesothelioma Malignant                                        1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 09:52:31  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            51          44          50          47                                       
     Total Primary Neoplasms                          110          90         126         122                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 49          39          46          40                                       
     Total Benign Neoplasms                            92          67          93          80                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              14          16          23          35                                       
     Total Malignant Neoplasms                         18          22          33          42                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              3           1           3           1                                       
     Total Metastatic Neoplasm                          4           1           6           7                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                              1                                                               
     Total Uncertain Neoplasms                                      1                                                               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.